Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | HTR1F | P30939 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 3/20 | 0.38 |
| ▸ | RAF1 | P04049 | 3/20 | 0.38 |
| ▸ | RORC | P51449 | 5/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13701988 | 0.88 | EPHX2 (0.50) | EPHX2CCR2GRM5BRAFRAF1 | |
| SCHEMBL13701901 | 0.85 | EPHX2 (0.48) | EPHX2BRAFRAF1 | |
| SCHEMBL4250822 | 0.82 | EPHX2 (0.54) | EPHX2GRM5BRAFRAF1 | |
| SCHEMBL4252925 | 0.79 | EPHX2 (0.78) | EPHX2GRM5 | |
| SCHEMBL13702361 | 0.78 | EPHX2 (0.51) | EPHX2HTR1AHTR1BHTR1FGRM5 | |
| SCHEMBL4248891 | 0.77 | EPHX2 (0.54) | EPHX2GRM5ADORA2A | |
| SCHEMBL4257104 | 0.77 | EPHX2 (0.55) | EPHX2HTR1AHTR1BHTR1FGRM5 | |
| SCHEMBL4251778 | 0.76 | EPHX2 (0.56) | EPHX2GRM5BRAF | |
| SCHEMBL13701919 | 0.75 | EPHX2 (0.54) | EPHX2BRAFRAF1 | |
| SCHEMBL13701889 | 0.75 | EPHX2 (0.71) | EPHX2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| WO-2007067836-A2 | SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | EPHX2 2/4885CCR2 4603/4885HTR1A 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.